
Opinion|Videos|January 29, 2025
MagnestisMM: Key Efficacy Data and its Clinical Implications
In this segment, Dr. Mohan asks Dr. Mann to summarize the key efficacy data from the MagnestisMM trials evaluating the use of elranatamab in relapsed/refractory multiple myeloma (R/R MM).
Advertisement
Episodes in this series

Video content above is prompted by the following:
Can you summarize the key efficacy data from the MagnestisMM trials evaluating the use of elranatamab in R/R MM?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Ficerafusp Alfa/Pembrolizumab Receives FDA BTD in Front-Line HNSCC
2
Tucatinib Regimen Improves PFS in HER2+ Metastatic Breast Cancer
3
ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors
4
Safety Strategies for GPRC5D-Directed and T-Cell Engager Therapies
5